Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Pancreatic Adenocarcinoma

• Status: Recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced, recurrent, or metastatic pancreatic adenocarcinoma as first line therapy. The phase 1b portion of the study is open label and patients will receive AVB-S6-500, nab-paclitaxel, and gemcitabine. The Phase 2 portion of the study is randomized, 2-arm, open-label study to compare efficacy and tolerability of AVB-S6-500, nab-paclitaxel, and gemcitabine versus nab-paclitaxel and gemcitabine as first line therapy.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aravive, Inc.
• Treatments: Gemcitabine; Paclitaxel

Criteria

Inclusion Criteria:

• Age 18 years or older

• Histologically or cytologically confirmed pancreatic adenocarcinoma. Must have locally advanced, recurrent, or metastatic disease ineligible for curative intent treatment(s) and eligible for first line systemic treatment.

• Must have radiologic imaging with a computed tomography (CT) scan or magnetic resonance imaging (MRI) within 22 days of study entry

• Must have at least one measurable lesion according to RECIST 1.1

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

• Adequate gastrointestinal (GI), bone marrow, liver and kidney function

• Life expectancy minimum of > 12 weeks

• Adequate recovery from surgery to Grade 1 or baseline with at least 28 days from time of major surgery

Exclusion Criteria:

• Received last dose of chemotherapy (neoadjuvant or adjuvant), surgery, or radiation treatment with curative intent within 6 months prior to study entry

• Islet-cell neoplasms

• Prior malignancy within the past 3 years except adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast

• Symptomatic uncontrolled central nervous system (CNS) metastasis or brain metastases unless adequately treated and controlled

• Evidence of clinically significant third spacing (e.g. pleural effusion, ascites, anasarca, etc.) within 28 days prior to study entry

• Serious active infection requiring IV antibiotics and/or hospitalization at study entry

• Active human immune deficiency (HIV) syndrome, hepatitis B, hepatitis C, or other active viral illness